Commemorating 25 years of fighting pancreatic cancer
Learn More

Hirshberg Foundation for Pancreatic Cancer Research

Dedicated to advancing pancreatic cancer research and providing support to patients and their families.

Donate
  • ABOUT THE FOUNDATION
    • Agi’s Story
    • About Us →
      • Mission
      • Directors/Trustees
      • Scientific Advisory Board
      • How Our Journey Began
    • COVID-19 Resources
    • News →
      • Latest News
      • Research News
      • Foundation News
      • UCLA Activity Summary Reports
      • Newsletters
      • Press Room
    • Contact
  • PANCREATIC CANCER
    • About the Pancreas →
      • The Pancreas
      • Cancer Cells
      • Risk Factors
      • Symptoms
      • Diagnosis
      • Prognosis
      • Staging
      • Second Opinion
    • Treatment Options →
      • Surgery
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Alternative Treatment Options
      • Clinical Trials
    • Supportive Care →
      • Obstructions
      • Pain Control
      • Nutrition
      • Cannabis
      • Palliative Care
    • Pancreatic Cancer Facts
    • Glossary of Terms
    • Frequently Asked Questions
  • RESEARCH
    • Seed Grant Program →
      • Seed Grant Recipients
      • Frequently Asked Questions
    • UCLA Program →
      • UCLA Center for Pancreatic Diseases
      • Basic Research
      • Translational Research
      • Sahin-Toth Laboratory
      • UCLA Pancreas Tissue Bank
      • UC Pancreatic Cancer Consortium
      • Simms/Mann Psychosocial →
        • Insights into Cancer
    • American Pancreatic Association
    • NIH Funded Projects
  • PATIENTS & CAREGIVERS
    • Patient Support
    • Caregivers
    • Symposium →
      • Symposium Presentations
    • Patient & Family Webinars
    • Genetic Counseling
    • Financial Aid
    • Resources →
      • Symptom Management Workbook
      • Guidelines for Patients: Pancreatic Cancer
      • Creating Your Health Care Team
      • A Virtual Advocate
      • Patient Tools
  • HOW YOU CAN HELP
    • You Can Help Funds
    • Host Your Own Event
    • Event Calendar
    • Get Inspired
    • November Awareness Month →
      • World Pancreatic Cancer Day
    • Other Ways to Give →
      • Shop Online Store
      • Wedding Program
      • Volunteer
      • Planned Giving
      • Car Program
  • SEARCH
Home / Research / Seed Grant Program / Seed Grant Recipients / Wei Wang, MD

Wei Wang, MD

Wei Wang, MD
Wei Wang, MD
Postdoctoral research fellow

Department of Surgery

NYU School of Medicine
New York, NY

Targeting microbiome to enable efficacy for immunotherapy in PDA

Overview

Aim: Cancer Therapy

Systemic chemotherapy remains the standard care of therapy for advanced pancreatic cancer; however, it has limited efficacy. Immunotherapy has developed into a transformative treatment option in several malignancies, but pancreatic tumors have proven resistant to this approach. This resistance is caused by a relatively cold tumor microenvironment, making the immune system insensitive to target tumors. The sum of bacteria inhabiting the human body, collectively known as the microbiome, is emerging as an important regulator in the balance between health and disease. We hypothesized that the microbiome plays an important role in shaping the immune-suppressive environment in PDA. Accordingly, we recently reported that the cancerous pancreas harbors a markedly more abundant and distinctive microbiome compared to normal pancreas in humans and in mouse models (Cancer Discovery 2018). We showed that the microbiome exerts potent immune-suppressive influences on pancreatic cancers and can be targeted to improve outcomes in mice. We also found that by reversing immune suppression, targeting the microbiome enabled efficacy for immunotherapy that otherwise failed. We propose to perform experiments in both mouse models and in human 3-dimentional cancer models which are aimed at defining the most efficacious microbiome modulatory regimens – either antibiotics and/or probiotics – to combine with immunotherapy. Collectively, these foundational studies will provide rationale for the transformative clinical trial that will lead to a new treatment paradigm for pancreatic cancer patients that involves reconfiguring the microbiome to enable immunotherapeutic responsiveness in patients.

Research

  • Seed Grant Program
    • Seed Grant Recipients
      • Alexandra Demcsak M.D., Ph.D.
      • Evan R. Abt, Ph.D.
      • Jason Link, Ph.D.
      • Kamini Singh Ph.D.
      • Ethan V Abel, PhD
      • Michael Feigin, Ph.D.
      • Mirunalini Ravichandran, Ph.D.
      • Simon Schwörer, Ph.D.
      • Vanaja Konduri, Ph.D.
    • Frequently Asked Questions
  • UCLA Program
    • UCLA Center for Pancreatic Diseases
    • Basic Research
    • Translational Research
    • Sahin-Toth Laboratory
    • UCLA Pancreas Tissue Bank
    • UC Pancreatic Cancer Consortium
    • Psychosocial Care via Simms/Mann
      • Insights into Cancer
  • American Pancreatic Association (APA)
  • NIH Funded Projects

Patient Support Resources

from the comfort of your home


Our Webinar Library »

Never Give Up.
The journey continues with an end in sight.
Our Stories »
SUBSCRIBE
Our Free E-Newsletter
Sign up to receive information on breaking news, patient programs and upcoming events.
You can custom tailor your subscriptions and unsubscribe at any time.
  • How You Can Help
  • Make A Donation
  • Host an Event
  • Shop Online Store
  • Signature Events
  • L.A. Cancer Challenge
  • Tour De Pier
  • Hirshberg Training Team
  • More
  • News
  • Press
  • Contact

Stay Connected

Join Our E-newsletter

  • Legal and Privacy
  • Contact Us